Mirati Therapeutics Q2 EPS $(3.04) Beats $(3.23) Estimate, Sales $13.69M Miss $13.92M Estimate
Portfolio Pulse from totan@benzinga.com
Mirati Therapeutics reported Q2 earnings per share (EPS) of $(3.04), beating the estimate of $(3.23) by 5.88%. However, the company's sales of $13.69M missed the estimate of $13.92M by 1.65%. The EPS is a 4.4% increase from last year, while the sales represent a 155.32% increase from the same period last year.
August 08, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Mirati Therapeutics' Q2 EPS beat estimates but sales missed. This mixed result could lead to uncertain short-term price movement.
Mirati Therapeutics reported better than expected EPS but lower than expected sales for Q2. This mixed result could lead to uncertainty in the market, potentially causing short-term price volatility.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100